07:26 AM EDT, 08/27/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) saidon Tuesday that it will present two abstracts, both as oral presentations, at the Promise of Interleukin-2 Therapy Conference, in Paris, France, next week.

The company will present preclinical data for the first time on its MDNA209 platform, featuring long-acting super-antagonists with therapeutic potential for autoimmune and graft-versus-host diseases. Additionally, further preclinical data will be presented on MDNA113, a novel first-in-class targeted therapy that is activated by cancer specific enzymes, Medicenna said.